This 2005 review compares the clinical and pharmacological profiles of magnesium sulfate (MgSO₄) and magnesium chloride (MgCl₂). While both compounds deliver magnesium ions, MgCl₂ demonstrates superior absorption, cellular penetration, and retention. Additionally, MgCl₂ exhibits lower tissue toxicity and more favorable membrane and antihypoxic properties. The authors suggest that MgCl₂ may
This phase II clinical trial evaluated the efficacy and safety of combining arsenic trioxide (ATO) with ascorbic acid (AA) in patients with acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (APL). Eleven patients, including elderly individuals unfit for intensive chemotherapy, received intravenous ATO (0.25 mg/kg/day) and AA (1 g/day) for
This Phase I clinical trial (NCT03051477) evaluates the safety, toxicity, and maximum tolerated dose (MTD) of Helixor® M (mistletoe extract) in 21 patients with advanced solid tumors who have not responded well to first-line therapies. The study consists of a dose escalation phase to assess safety and an expansion phase
The 2012 study “Glutamine: A novel approach to chemotherapy-induced toxicity” (DOI: 10.4103/0971-5851.96962) reviews the potential of glutamine supplementation to reduce the adverse effects of chemotherapy, such as mucositis, cardiotoxicity, neurotoxicity, and gastrointestinal damage. The study highlights glutamine’s protective role in supporting immune function, mitigating side effects, and enhancing recovery during
This preclinical study investigated the combined effects of high-dose intravenous vitamin C (ascorbate, Asc) and alpha-lipoic acid (ALA) on six human cancer cell lines and a mouse model of metastatic breast cancer. While high-dose Asc alone demonstrated tumor-inhibitory effects without toxicity, ALA did not inhibit tumor growth and instead increased
